HEMOSATE ULTRA HS2125 6.91 G
CITRIC ACID : 6.91 G CALCIUM CHLORIDE : 6.24 G MAGNESIUM CHLORIDE : 2.14 G DEXTROSE : 49.5 G SODIUM CHLORIDE : 263 G SODIUM ACETATE : 1.11 G POTASSIUM CHLORIDE : 6.71 G · DIN 02413906 · CHIEF MEDICAL SUPPLIES LTD
Health Canada status: MARKETED
What is HEMOSATE ULTRA HS2125?
HEMOSATE ULTRA HS2125 6.91 G contains CITRIC ACID : 6.91 G CALCIUM CHLORIDE : 6.24 G MAGNESIUM CHLORIDE : 2.14 G DEXTROSE : 49.5 G SODIUM CHLORIDE : 263 G SODIUM ACETATE : 1.11 G POTASSIUM CHLORIDE : 6.71 G. It is listed in the Health Canada Drug Product Database under DIN 02413906, held by CHIEF MEDICAL SUPPLIES LTD, supplied as SOLUTION for HAEMODIALYSIS administration. Health Canada currently lists it as marketed, status dated 15-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEMOSATE ULTRA HS2125 used for?
Hemosate Ultra HS2125 is indicated for use as the “Acid” component of a two-component mixture use for hemodialysis treatment for patients suffering from renal insufficiency. One part of this acid concentrate solution must be diluted with 1.72 parts of concentrated Sodium Bicarbonate solution, and 42.28 parts purified water USP to make a dialysate that is used for the hemodialysis treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02413906 |
|---|---|
| Brand name | HEMOSATE ULTRA HS2125 |
| Generic / active ingredient | CITRIC ACID : 6.91 G CALCIUM CHLORIDE : 6.24 G MAGNESIUM CHLORIDE : 2.14 G DEXTROSE : 49.5 G SODIUM CHLORIDE : 263 G SODIUM ACETATE : 1.11 G POTASSIUM CHLORIDE : 6.71 G |
| Manufacturer | CHIEF MEDICAL SUPPLIES LTD |
| Strength | 6.91 G |
| Dosage form | SOLUTION |
| Route of administration | HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZA HEMODIALYTICS, CONCENTRATES |
| AHFS class | 40:34.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Jan-2021 |
| Original market date | 2020-02-26 00:00:00 |
How is it stored and handled?
Store at room temperature (15 - 30 o C). Do not freeze.
How is it supplied?
4.5 L and 5 L polyethylene containers
What can be used instead?
Other Canadian products sharing ATC code B05ZA HEMODIALYTICS, CONCENTRATES. 117 of 588 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02533774 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.